Nasus Pharma Ltd. (NSRX) - Total Assets
Based on the latest financial reports, Nasus Pharma Ltd. (NSRX) holds total assets worth $5.00 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore NSRX cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Nasus Pharma Ltd. - Total Assets Trend (2022–2025)
This chart illustrates how Nasus Pharma Ltd.'s total assets have evolved over time, based on quarterly financial data. See net assets of Nasus Pharma Ltd. for net asset value and shareholders' equity analysis.
Nasus Pharma Ltd. - Asset Composition Analysis
Current Asset Composition (December 2025)
Nasus Pharma Ltd.'s total assets of $5.00 Million consist of 97.0% current assets and 3.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 24.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how Nasus Pharma Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Nasus Pharma Ltd..
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nasus Pharma Ltd.'s current assets represent 97.0% of total assets in 2025, a decrease from 100.0% in 2022.
- Cash Position: Cash and equivalents constituted 24.7% of total assets in 2025, down from 36.9% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Nasus Pharma Ltd. Competitors by Total Assets
Key competitors of Nasus Pharma Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
Virbac SA
PA:VIRP
|
France | €1.82 Billion |
|
Aurora Optoelectronics Co Ltd
SHG:600666
|
China | CN¥2.22 Billion |
|
NanJing Pharmaceutical Co Ltd
SHG:600713
|
China | CN¥34.05 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$3.66 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$112.48 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$207.62 Billion |
Nasus Pharma Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.24 | 0.12 | 0.10 |
| Quick Ratio | 2.24 | 0.12 | 0.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.69 Million | $-3.47 Million | $-3.80 Million |
Nasus Pharma Ltd. - Advanced Valuation Insights
This section examines the relationship between Nasus Pharma Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.42 |
| Latest Market Cap to Assets Ratio | 6.79 |
| Asset Growth Rate (YoY) | 597.9% |
| Total Assets | $5.00 Million |
| Market Capitalization | $33.96 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Nasus Pharma Ltd.'s assets at a significant premium (6.79x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Nasus Pharma Ltd.'s assets grew by 597.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Nasus Pharma Ltd. (2022–2025)
The table below shows the annual total assets of Nasus Pharma Ltd. from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $5.00 Million | +597.91% |
| 2024-12-31 | $717.00K | +61.49% |
| 2023-12-31 | $444.00K | +6.47% |
| 2022-12-31 | $417.00K | -- |
About Nasus Pharma Ltd.
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS00… Read more